KAZIA THERAPEUTICS-SPON ADR (KZIA) Stock Price & Overview
NASDAQ:KZIA • US48669G3039
Current stock price
The current stock price of KZIA is 7.49 USD. Today KZIA is down by -6.49%. In the past month the price increased by 45.72%. In the past year, price increased by 50.52%.
KZIA Key Statistics
- Market Cap
- 84.907M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.18
- Dividend Yield
- N/A
KZIA Stock Performance
KZIA Stock Chart
KZIA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to KZIA. When comparing the yearly performance of all stocks, KZIA is one of the better performing stocks in the market, outperforming 74.2% of all stocks.
KZIA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KZIA. KZIA may be in some trouble as it scores bad on both profitability and health.
KZIA Earnings
On November 7, 2025 KZIA reported an EPS of 1.42 and a revenue of 42.00K. The company beat EPS expectations (207.09% surprise) and beat revenue expectations (414.71% surprise).
KZIA Forecast & Estimates
8 analysts have analysed KZIA and the average price target is 19.38 USD. This implies a price increase of 158.74% is expected in the next year compared to the current price of 7.49.
For the next year, analysts expect an EPS growth of 79.58% and a revenue growth -25.37% for KZIA
KZIA Groups
Sector & Classification
KZIA Financial Highlights
Over the last trailing twelve months KZIA reported a non-GAAP Earnings per Share(EPS) of -2.18. The EPS increased by 93.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -158.6% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KZIA Ownership
KZIA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 388.432B | ||
| AMGN | AMGEN INC | 16.04 | 197.413B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 179.993B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 119.226B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.843B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 41.564B | ||
| INSM | INSMED INC | N/A | 30.069B | ||
| BIIB | BIOGEN INC | 11.29 | 26.644B | ||
| NTRA | NATERA INC | N/A | 26.624B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.498B | ||
| MRNA | MODERNA INC | N/A | 20.758B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.77B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.798B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KZIA
Company Profile
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Company Info
IPO: 1994-09-01
KAZIA THERAPEUTICS-SPON ADR
Three International Towers Level 24,, 300 Barangaroo Avenue
Sydney NEW SOUTH WALES 2000 AU
CEO: James Garner
Employees: 6
Phone: 1161298780088
KAZIA THERAPEUTICS-SPON ADR / KZIA FAQ
What does KZIA do?
Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. The company is headquartered in Sydney, New South Wales. The firm operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. The company designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
What is the current price of KZIA stock?
The current stock price of KZIA is 7.49 USD. The price decreased by -6.49% in the last trading session.
What is the dividend status of KAZIA THERAPEUTICS-SPON ADR?
KZIA does not pay a dividend.
What is the ChartMill technical and fundamental rating of KZIA stock?
KZIA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the employee count for KZIA stock?
KAZIA THERAPEUTICS-SPON ADR (KZIA) currently has 6 employees.
What is the market capitalization of KZIA stock?
KAZIA THERAPEUTICS-SPON ADR (KZIA) has a market capitalization of 84.91M USD. This makes KZIA a Micro Cap stock.
What is the ownership structure of KAZIA THERAPEUTICS-SPON ADR (KZIA)?
You can find the ownership structure of KAZIA THERAPEUTICS-SPON ADR (KZIA) on the Ownership tab.